Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q)

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pardanani A, Lasho TL, Finke C, Mai M, McClure RF, Tefferi A . IDH1 and IDH2 mutation analysis in chronic and blast phase myeloproliferative neoplasms. Leukemia 2010, e-pub ahead of print 22 April 2010.

  2. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058–1066.

    Article  CAS  Google Scholar 

  3. Patnaik MM, Lasho TL, Finke C, Gangat N, Caramazza D, Holtan SG et al. WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia 2010, e-pub ahead of print 20 May 2010.

  4. Tefferi A, Vardiman JW . Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872–1885.

    Article  CAS  Google Scholar 

  5. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H . IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174: 1149–1153.

    Article  CAS  Google Scholar 

  6. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H . IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009; 15: 6002–6007.

    Article  CAS  Google Scholar 

  7. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010; 24: 105–109.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study is supported, in part, by grants from the Myeloproliferative Disorders Foundation, Chicago, IL, USA. AP is partially supported by a grant from the Henry J Predolin Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A Tefferi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pardanani, A., Patnaik, M., Lasho, T. et al. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia 24, 1370–1372 (2010). https://doi.org/10.1038/leu.2010.98

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2010.98

This article is cited by

Search

Quick links